Antibody useful in neurological or neurodegenerative disorders

Patent metadata

Field	Value
Publication number	US-10072077-B2
Application number	US-201414890613-A
Country	US
Kind code	B2
Filing date	May 21, 2014
Priority date	May 21, 2013
Publication date	Sep 11, 2018
Grant date	Sep 11, 2018

Abstract

The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.

First claim

The invention claimed is:

1. An anti-NMDA receptor monoclonal antibody, which inhibits the interaction between the NMDA receptor and t-PA whereby at least one function of the NMDA receptor is selectively inhibited, wherein said monoclonal antibody
comprises the complementarity determining regions (CDRs) having the amino acid sequences consisting of SEQ ID NOs: 29, 30, 31, 32, 33 and 34.

2. The anti-NMDA receptor monoclonal antibody according to claim 1 , which
comprises a complete heavy chain framework region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 35, 36, 37 and 38 and a complete light chain framework region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 39, 40, 41 and 42.

3. The anti-NMDA receptor monoclonal antibody according to claim 1 , which comprises one or two heavy chain variable regions comprising the amino acid sequence of SEQ ID NO: 43 and/or which comprises one or two light chain variable regions comprising the amino acid sequence of SEQ ID NO:44.

4. A pharmaceutical composition comprising the anti-NMDA receptor monoclonal antibody according to claim 1 , and one or more components selected from the group consisting of carriers, solvents, diluents, and excipients.

5. The anti-NMDA receptor monoclonal antibody according to claim 1 produced by a deposited hybridoma consisting of 15A4B2E5.

6. The anti-NMDA receptor monoclonal antibody according to claim 1 which is a humanized antibody.

7. An antibody produced by a deposited hybridoma consisting of 15A4B2E5.

8. The antibody according to claim 7 which is a humanized antibody.

Assignees

• Paion Deutschland Gmbh
• Inst Nat Sante Rech Med
• Paion Deutschland
• Inst Nat Sante Rech Med
• Univ Caen

Inventors

• Docagne Fabian
• Macrez Richard
• Vivien Denis
• Petersen Karl-Uwe

Classifications

• A61P7/10

  Antioedematous agents; Diuretics · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61P31/12

  Antivirals · CPC title